ZYBT Market Analysis
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.78
- P/S (TTM)
- 0.56
- EV/EBITDA
- 21.76
Profitability & growth
- ROE (TTM)
- -25.2%
- Operating margin
- -77.0%
- Revenue growth YoY
- -40.9%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Zhengye Biotechnology Holding Limited Ordinary Shares
Company profileZhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm specializing in the development and commercialization of advanced biopharmaceutical products aimed at addressing critical medical needs. With a robust pipeline and proprietary technologies, ZYBT is well-positioned to enhance treatment outcomes across multiple therapeutic areas. The company's commitment to rigorous research and development, coupled with a focus on quality and innovation, underscores its potential for sustainable growth and value creation for investors in the competitive biotechnology…
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- NO.1 LIANMENG ROAD, JILIN, CHINA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer